Drugs / Alfacalcidol
Alfacalcidol
also known as
Alphacalcidol · 1-hydroxycholecalciferol · 1 alpha-hydroxyvitamin D3 · 1-alpha OH vitamin D · Alfarol · Etalpha
Trials 22
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 24 trials | ||||||
| Phase 2 | NCT04166253 | Sep 2019 → Apr 2020 | breast cancer | Damanhour University | Completed | No outcome recorded |
| Phase 2 | NCT03582917 | Sep 2018 → Dec 2025 overdue | adolescent idiopathic scoliosis | University of Ioannina | Recruiting | No outcome recorded |
| Phase 2 | NCT01364688 | May 2011 → Nov 2012 | calcinosis | Ramathibodi Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT01231438 | Oct 2010 → Mar 2011 | kidney failure | Helse Stavanger HF | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT06016400 | Jun 2021 → Apr 2024 | chemotherapy-induced oral mucositis, oral cavity squamous cell carcinoma | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Unknown | No outcome recorded |
| Phase 33 trials · 2 met primary | ||||||
| Phase 3 | NCT04405960 | Jul → Sep 2017 | osteoarthritis, knee | Syarif Hidayatullah State Islamic University Jakarta | Completed | No outcome recorded |
| Phase 3 | NCT00144456 | Sep 2004 → Sep 2008 | osteoporosis | Chugai Pharmaceutical | Completed | Met primary |
| Phase 3 | NCT00138983 | May 2000 → Nov 2003 | granulomatosis with polyangiitis, polymyalgia rheumatica, polymyositis, rheumatoid arthritis +1 | UMC Utrecht | Completed | Met primary |
| Phase 410 trials · 1 met primary · 1 missed | ||||||
| Phase 4 | NCT06272227 | Feb 2024 → Sep 2025 | muscular atrophy | Yonsei University | Unknown | No outcome recorded |
| Phase 4 | NCT03210688 | May 2018 → Feb 2024 | minimal change disease, nephrotic syndrome | University of Aarhus | Completed | Missed primary |
| Phase 4 | NCT04085770 | Apr 2017 → Feb 2018 | cardiac valvular defect | Cairo University | Completed | Met primary |
| Phase 4 | NCT03292744 | Jan → Oct 2017 | — | Indonesia University | Unknown | No outcome recorded |
| Phase 4 | NCT03147677 | Jul 2016 → Jul 2018 | diabetic kidney disease | The Third Xiangya Hospital of Central South University | Completed | No outcome recorded |
| Phase 4 | NCT02338934 | Jan 2015 → Jan 2017 | secondary hyperparathyroidism | Penang Hospital, Malaysia | Unknown | No outcome recorded |
| Phase 4 | NCT01765010 | Jan → Mar 2013 | osteoporosis | Seoul National University Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT01115543 | Aug 2008 → Aug 2009 | end stage renal failure, secondary hyperparathyroidism of renal origin | Mahidol University | Completed | No outcome recorded |
| Phase 4 | NCT00483275 | Jun 2007 → Sep 2009 | chronic kidney disease | Ruhr University of Bochum | Withdrawn | No outcome recorded |
| Phase 4 | NCT00168909 | Jun 2003 → Jul 2007 | postmenopausal osteoporosis | Charite University, Berlin, Germany | Completed | No outcome recorded |
| Phase not applicable4 trials · 1 met primary | ||||||
| — | NCT04967469 | Sep 2020 → Dec 2023 | end stage renal failure | Department of Medical Services Ministry of Public Health of Thailand | Completed | No outcome recorded |
| — | NCT03777033 | Mar 2015 → Apr 2020 | thyroid gland disorder | Hellenic Red Cross Hospital | Unknown | No outcome recorded |
| — | NCT02895061 | Jan → Oct 2015 | secondary hyperparathyroidism of renal origin | Phramongkutklao College of Medicine and Hospital | Completed | No outcome recorded |
| — | NCT00828347 | Jan 2008 → Jul 2009 | secondary hyperparathyroidism of renal origin | Kumamoto University | Completed | Met primary |
| Comparator or background therapy12 trials | ||||||
| Phase 2 | NCT03183557 Comparator | Oct 2017 → Dec 2022 | osteoporosis | Shinshu University | Unknown | No outcome recorded |
| Phase 2 | NCT02824718 Comparator | Jun 2017 → May 2020 | autosomal dominant hypocalcemia | Assistance Publique - Hôpitaux de Paris | Completed | No outcome recorded |
| Phase 3 | NCT05505253 Comparator | Nov 2020 → Oct 2021 | pelvic organ prolapse | Padjadjaran University | Completed | No outcome recorded |
| Phase 3 | NCT02327091 Comparator | Apr → Sep 2012 | myopathy | Indonesia University | Completed | No outcome recorded |
| Phase 3 | NCT00165698 Comparator | May 2005 → Jan 2007 | postmenopausal osteoporosis | Eisai Inc. | Completed | No outcome recorded |
| Phase 4 | NCT06385093 Comparator | Jun 2024 → Dec 2025 | osteoporosis, rheumatoid arthritis | Chinese SLE Treatment And Research Group | Unknown | No outcome recorded |
| Phase 4 | NCT01430104 Background | Aug → Dec 2011 | osteoporosis | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 4 | NCT01181531 Comparator | Oct 2010 → Jul 2012 | secondary hyperparathyroidism | Amgen | Completed | Missed primary |
| Phase 4 | NCT00668330 Comparator | Apr 2007 → May 2009 | systemic lupus erythematosus | Chinese University of Hong Kong | Completed | No outcome recorded |
| — | NCT01974167 Comparator | Dec 2013 → Feb 2018 | osteoporosis | e-GLORIA trial Protocol Review Committee | Unknown | No outcome recorded |
| — | NCT00469599 Comparator | Jul 2007 → Sep 2010 | chronic kidney disease, secondary hyperparathyroidism of renal origin, vitamin D deficiency | Zealand University Hospital | Terminated | No outcome recorded Stop: Enrollment |
| — | NCT01020253 Comparator | Jan 2006 → Apr 2008 | bone disorder | Yokohama City University Medical Center | Unknown | No outcome recorded |
Evidence & citations 10 cited values
Every value below carries the sentence it was read from. 36 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Alfacalcidol | “the Prophylactic protocol with Ca and Vit D will be given in the form of Alfacalcidol 0.5 Micrograms Capsule and CALCIUM CARBONATE + CALCIUM GALACTOGLUCONATE 1000mg tablet” NCT03777033 ↗29“Traditional vitamin D therapy (eg, calcitriol, paricalcitol, alfacalcidol, doxercalciferol), to manage secondary hyperparathyroidism (SHPT)” NCT01181531 ↗ “Alfacalcidol oral tablets once daily” NCT04166253 ↗ |
| Known as | 1 alpha-hydroxyvitamin D3 | “Vitamin D therapy, particularly alfacalcidol [1 alpha-hydroxyvitamin D3], has been shown to be effective in the treatment of secondary hyperparathyroidism.” PMID 16792136 ↗ Jun 2006 |
| Known as | 1-alpha OH vitamin D | “Alendronate versus alfacalcidol (1-alpha OH vitamin D)” NCT00138983 ↗ |
| Known as | 1-hydroxycholecalciferol | “receive either monthly oral ibandronate (150 mg) or placebo with daily 1-hydroxycholecalciferol (Alfacalcidol; 1 μg) and calcium supplement for 12 months.” PMID 20964867 ↗ Oct 20101“End-stage renal failure patients who is Hyperparathyroid with ESRD take 1-hydroxycholecalciferol (alfacalcidol)” NCT04967469 ↗ |
| Known as | Alfarol | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01430104 ↗ |
| Known as | Alphacalcidol | “This study aims to determine the effect of Vitamin D supplementation (Alphacalcidol) on pain and joint cartilage condition in elderly patients with knee OA.” NCT04405960 ↗2“Vitamin D analogues such as alphacalcidol are needed to bring their iPTH levels down to normal.” NCT02338934 ↗ |
| Known as | Etalpha | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01231438 ↗ |
| Action | Inhibit | “for their efficacy on suppression of PTH” NCT01115543 ↗ |
| Modality | Other / unclassified | “In Denmark alfacalcidol is the primary choice of vitamin D analog.” NCT00469599 ↗ |
| Route | Oral | “1.0μg/day(p.o.)for 144 weeks” NCT00144456 ↗ |